Zubakov Dmitry, Stupar Zorica, Kovacs Gyula
Laboratory of Molecular Oncology, Medical Faculty, Ruprecht-Karls-University, Heidelberg, Germany.
BMC Cancer. 2006 Apr 26;6:106. doi: 10.1186/1471-2407-6-106.
Renal oncocytoma, a benign tumour of the kidney, may pose a differential diagnostic problem due to overlapping phenotype with chromophobe renal cell carcinoma or other types of renal cell tumours. Therefore, identification of molecular markers would be of great value for molecular diagnostics of this tumour type.
In the current study we applied various techniques, including Affymetrix microarray hybridization and semiquantitative RT-PCR, to identify genes expressed differentially in renal oncocytomas. Subsequently, we used RACE and Northern blot hybridization to characterize the potential candidates for molecular diagnosis.
We have identified new isoform of DLG2 gene, which contains 3'-end exons of the known DLG2 gene along with the hypothetical gene FLJ37266. The new isoform is specifically upregulated in renal oncocytoma, whereas the known DLG2 gene is downregulated in this type of kidney tumour.
The new isoform of DLG2 is the promising candidate gene for molecular differential diagnostics of renal oncocytoma.
肾嗜酸细胞瘤是一种肾脏良性肿瘤,由于其与嫌色肾细胞癌或其他类型肾细胞肿瘤的表型重叠,可能会带来鉴别诊断问题。因此,鉴定分子标志物对于这种肿瘤类型的分子诊断具有重要价值。
在本研究中,我们应用了多种技术,包括Affymetrix微阵列杂交和半定量RT-PCR,以鉴定在肾嗜酸细胞瘤中差异表达的基因。随后,我们使用RACE和Northern印迹杂交来表征分子诊断的潜在候选基因。
我们鉴定出DLG2基因的新异构体,它包含已知DLG2基因的3'端外显子以及假设基因FLJ37266。这种新异构体在肾嗜酸细胞瘤中特异性上调,而已知的DLG2基因在这种类型的肾肿瘤中下调。
DLG2的新异构体是肾嗜酸细胞瘤分子鉴别诊断的有前景的候选基因。